Trials / Unknown
UnknownNCT03681938
Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?
Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission After 2 Cycles of Chemotherapy ?
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 183 (actual)
- Sponsor
- Institut Paoli-Calmettes · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The autograft of patients with prognostically unfavourable B-cells lymphoma cells in first remission remains controversial, in particular since the association of Rituximab with chemotherapy. Even though many randomized and non-randomized studies have been conducted, their is still no standard procedure . Recently, the use of early TEP (positron emission topography) answer, after 2 in 3 cures of chemotherapy allowed to select the poor-responder patients who remain candidate to autograft in front-line. Nevertheless, in good-responder patients, the benefits of an intensification therapy ins term of long-lasting disease control remains discussion. This institutional retrospective study aims at comparing the outcome of early metabolic responder patients who received an intensification treatment to those who received a standard chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Autograft | Autograft |
Timeline
- Start date
- 2017-07-03
- Primary completion
- 2019-07-28
- Completion
- 2019-07-28
- First posted
- 2018-09-24
- Last updated
- 2018-09-24
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03681938. Inclusion in this directory is not an endorsement.